help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nordal, K. P.
Right arrow Articles by Dahl, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nordal, K. P.
Right arrow Articles by Dahl, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*1,25-DIHYDROXYCHOLECALCIFEROL
*ALUMINUM
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
*PARATHYROID HORMONE

Journal of Clinical Endocrinology & Metabolism, Vol 67, 929-936, Copyright © 1988 by Endocrine Society

ARTICLES

Low dose calcitriol versus placebo in patients with predialysis chronic renal failure

KP Nordal and E Dahl
Medical Department B, National Hospital, Oslo, Norway.

The effects of a small dose of calcitriol (less than or equal to 0.50 micrograms/day) on parathyroid and renal function, bone histomorphometry, and aluminum (Al) metabolism were studied in a randomized double blind study of 30 patients with predialysis chronic renal failure. The patients were followed at least monthly for 8 months. Serum Al levels were measured, and transiliac bone biopsies, double labeled with tetracycline, were obtained at both the beginning and end of the 8-month treatment period. Serum calcium and ionized calcium concentrations increased in the treatment group, and the calcitriol dosage had to be reduced in 8 patients at least once because of hypercalcemia. Calcitriol treatment did not significantly influence either serum A1 levels or the presence of stainable Al in bone. Serum PTH, urinary cAMP excretion, and bone resorption indices decreased in the treatment group, indicating suppression of parathyroid hyperfunction. Throughout the study renal function decreased at a similar rate in both groups, suggesting that calcitriol treatment had no depressive effect on renal function. We conclude that a low dose of calcitriol may be used to preserve or even restore bone metabolism in patients with predialysis chronic renal failure if serum calcium is closely followed and hypercalcemia promptly treated.


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
C. P. Kovesdy, S. Ahmadzadeh, J. E. Anderson, and K. Kalantar-Zadeh
Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease
Arch Intern Med, February 25, 2008; 168(4): 397 - 403.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. C. Palmer, D. O. McGregor, P. Macaskill, J. C. Craig, G. J. Elder, and G. F.M. Strippoli
Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease
Ann Intern Med, December 18, 2007; 147(12): 840 - 853.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society